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Development and evaluation of a replicon
particle vaccine expressing the E2 glycoprotein of
bovine viral diarrhea virus (BVDV) in cattle
John Dustin Loy1,5*, Jill Gander1, Mark Mogler1,2, Ryan Vander Veen1, Julia Ridpath3, Delbert Hank Harris1,2,4
and Kurt Kamrud1,2
Abstract
Background: Bovine viral diarrhea virus is one of the most significant and costly viral pathogens of cattle
worldwide. Alphavirus-derived replicon particles have been shown to be safe and highly effective vaccine vectors
against a variety of human and veterinary pathogens. Replicon particles are non-propagating, DIVA compatible, and
can induce both humoral and cell mediated immune responses. This is the first experiment to demonstrate that
Alphavirus-based replicon particles can be utilized in a standard prime/boost vaccination strategy in calves against a
commercially significant bovine pathogen.
Findings: Replicon particles that express bovine viral diarrhea virus sub-genotype 1b E2 glycoprotein were
generated and expression was confirmed in vitro using polyclonal and monoclonal antibodies specific to E2.
Vaccine made from particles was generated in Vero cells and administered to BVDV free calves in a prime/boost
regimen at two dosage levels. Vaccination resulted in neutralizing antibody titers that cross-neutralized both type 1
and type 2 BVD genotypes following booster vaccination. Additionally, high dose vaccine administration
demonstrated some protection from clinical disease and significantly reduced the degree of leukopenia caused by
viral infection.
Conclusions: Replicon particle vaccines administered in a prime/boost regimen expressing BVDV E2 glycoprotein
can induce cross-neutralizing titers, reduce leukopenia post challenge, and mitigate clinical disease in calves. This
strategy holds promise for a safe and effective vaccine to BVDV.
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Findings
Background
Bovine viral diarrhea virus (BVDV) is an enveloped,
positive strand RNA virus in the genus Pestivirus (family
Flaviviridae), and is the causative agent of bovine viral
diarrhea (BVD). BVD is one of the most economically
significant bovine diseases in the world. Production
losses, estimated on a population level, are thought to be
$10–40 million US per million calvings [1]. Classically,
BVDV has been associated with acute enteric disease;
however, BVDV is now understood to be responsible for
a broad range of clinical illnesses in cattle including re-
spiratory disease, reproductive loss, and fetal infections
[2]. The BVDV E2 gene encodes a 53 kDa major struc-
tural glycoprotein that contains a neutralizing epitope
that varies among strains [3]. Monoclonal antibodies
specific to E2 demonstrate virus neutralizing (VN) ability
against both cytopathic and noncytopathic strains of
BVDV [4]. Current strategies to reduce losses caused by
BVD in infected herds include vaccination with modified
live (MLV) or inactivated vaccines and elimination of
persistently infected animals. There are no commercially
available recombinant or vectored vaccines, and thus
producers are limited to either modified live MLV or inac-
tivated vaccine approaches [5]. Additionally, some success
has been shown experimentally using BVD pseudovirions,
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which have a deletion in the structural genes, and are
rescued using homologous helper RNA in trans [6].
A replicon-based expression system has been derived
from the alphavirus (family Togaviridae) Venezuelan
Equine Encephalitis (VEE) virus [7,8]. Alphavirus-based
replicon particles have numerous advantages for vaccine
development including; accurate production of native
proteins and a propagation-defective nature that makes
the system only capable of a single infection cycle [9].
This viral vector has previously been used to express
genes from numerous pathogens including human
strains of influenza virus, simian immunodeficiency
virus, Norwalk virus, Ebola virus, smallpox virus, Lassa
virus, and equine arteritis virus [10-16]. RP have a robust
safety profile. It has been demonstrated that RP are not
shed from vaccinated animals and as such cannot spread
to unvaccinated animals. Furthermore, RP have been
tested for the presence of replication competent virus
that may arise by recombination during production of
RP and have been shown to lack the ability to revert to
virulence [17]. Alphavirus RP have also been tested in
cattle against foot and mouth disease virus (FMDV)
(Kurt Kamrud, personal communication) but have not
been tested against a commercially-significant cattle dis-
ease in the United States using a prime/boost vaccination
strategy. Therefore, it is proposed that alphavirus RP that
express the E2 glycoprotein from BVDV would provide a
novel, safe, and effective approach to control BVD.
Methods
The E2 glycoprotein gene was de novo synthesized
(DNA2.0) using sequence from BVDV subgenotype 1b
strain NY1 (Genbank: AY027671). The E2 gene was
cloned into a replicon vector plasmid as previously
described [8] and the sequence was confirmed to ensure
no mutations were introduced in the cloning process.
RNA was generated by in vitro transcription of linearized
replicon plasmid DNA using T7 RNA polymerase as
described previously [8]. RP were generated by co-
electroporation of E2 replicon RNA and structural gene
helper RNAs into Vero cells and subsequent harvest of
the particles [16]. Vero cell monolayers were then infected
with E2 RP at an MOI of 10 and the presence of E2
expression was confirmed by western blot analysis of E2
RP infected cell lysates using hyperimmune polyclonal
swine serum (data not shown). In addition, E2 protein ex-
pression was confirmed by indirect immunofluorescence
assay using E2 specific monoclonal antibodies (Figure 1).
Seven (7) calves, 8 weeks of age, were sourced from a
BVD free herd. Each animal was tested and found nega-
tive for BVDV antibodies by viral neutralization assay
(VN), BVDV antigen in earnotch samples (BVD immu-
nohistochemistry), and were negative for circulating
virus in whole blood by PCR. Three (3) calves were
randomly assigned to each of 2 blocks (experimental
groups) and one (1) calf was assigned to a single block
(placebo). The calves were acclimated for 7 days before
onset of the trial. Calves were injected intramuscularly
(IM) with 2 mL of 5 × 106 infectious units (IU)/mL RP
(1 × 107 IU total), 5 × 105 IU/mL RP (1 × 106 IU total), or
a placebo control of RP diluent (1% normal bovine
serum, 5% sucrose in PBS). Personnel sampling and
scoring the animals were blinded to the treatment
groups.
Figure 1 Indirect immunofluorescence assay of replicon particle (RP) infected Vero cells. Vero cell monolayers were infected with RP
expressing either (A) the E2 glycoprotein gene of BVDV subgenotype 1b strain NY1 or (B) a non-BVDV-derived gene as a control. Cells were fixed
and subsequently stained with a monoclonal antibody specific to BVDV 1b E2 and a fluorescent-conjugated anti-mouse secondary antibody.
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Serum was collected from calves on days 0, 21, 28, 35,
42, 49, and on 56. Whole blood was collected in tubes
containing EDTA 1 day prior to challenge through 14
days post challenge (a total of 16 days). On day 42 ani-
mals were challenged with 1×106 TCID50/mL of BVD1b
strain NY1 intranasally (USDA distributed efficacy chal-
lenge material). Neutralizing antibody responses were
assessed using representative viruses from Type 1 and
Type II BVDV strains (Singer and 296c, respectively)
using day 0, 21, 28, and 42 serum samples. Clinical
disease was scored on a scale from 0–3 each day. White
blood cell (WBC) counts were assessed on whole blood
samples collected in tubes containing EDTA using an
automated cell counter (Iowa State University, Veterinary
Pathology). The degree of leukopenia following virus chal-
lenge was assessed by subtracting the maximum reduction
in circulating WBCs from the baseline level (calculated
from a mean of two samples prior to challenge).
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Figure 3 Y-axis is percent depletion of circulating white blood cells when compared to pre-challenge baseline (set to 100%). The
highest levels of depletion were seen in the placebo groups with a dose dependent decrease in WBC reduction in vaccinated groups. Error bars
indicate standard error from mean percentage depletion.
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Figure 2 Geometric mean of viral neutralizing antibody dilutions on day of virus challenge. The 1×107 IU vaccinated group had
significantly higher geometric mean VN titers (P=.04 by oneway ANOVA) than the 1×106 IU dosage level. Reference strains used were Singer
(type 1) and 296c (type 2).
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Results
Serum from the control animal was VN negative on the
day of challenge. A dose dependent heterologous VN re-
sponse was observed in animals to sub-genotypes BVD1a
and BVD2. VN titers were induced in all vaccinated ani-
mals to Type 1 strains and most animals to Type 2 strains
in the high dose group. Significant differences by one-way
ANOVA were observed in VN geometric mean titers
between low and high dose E2 RP vaccinated groups
(Figure 2). The serum of all E2 RP vaccinated animals was
positive at termination by western immunoblotting against
recombinant E2 glycoprotein. Both E2 RP treated groups
showed a reduced degree of leukopenia when compared
with the control; the high dose E2 RP dose having a
greater impact on reducing leukopenia (Figure 3). Febrile
responses were noted in all animals at some study time-
point following virus challenge (Figure 4). The placebo
group demonstrated a febrile response before E2 RP vacci-
nated animals at 3 days post challenge (dpc) (Figure 4).
All experimental groups demonstrated febrile responses
from days 7–9 post challenge with a maximum of 105.8°F
(Figure 4). Temperatures returned to normal levels in all
E2 RP vaccinated animals by day 9 post challenge;
however, temperatures remained elevated for several
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Figure 5 Mean clinical scores over the course of the study. Scores were based on presence of mild nasal discharge, mild ocular discharge, or
mild depression. No differences were seen in clinical outcomes between low dose E2 RP and placebo controls in clinical disease.
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Figure 4 Mean rectal temperatures (°F) post challenge with BVD1b NY1 (Y-axis.) X-axis is days post viral challenge. Error bars indicate
standard error from mean.
Loy et al. Virology Journal 2013, 10:35 Page 4 of 5
http://www.virologyj.com/content/10/1/35
additional days in the control animal (Figure 4). Clinical
disease scores (nasal/ocular discharge and/or depression)
were collected for all animals. Protection from clinical dis-
ease after challenge was noted in 2 of the 3 high dose E2
RP vaccinated animals. The clinical disease scores for the
low dose E2 RP group and placebo control were not differ-
ent (mean clinical score = 4); In contrast, the high dose E2
RP group demonstrated significantly reduced disease
severity and degree of clinical signs (mean clinical score =
0.66) (Figure 5).
In summary, these data demonstrate that RP expressing
BVD1b NY1 E2 glycoprotein can induce dose dependent
immune responses specific to BVDV. Importantly, the E2
RP induce a cross-reactive VN antibody response to Type
1a and Type 2 BVD strains. This response was signifi-
cantly higher in animals that received the 1 × 107 IU E2
RP dosage level. Furthermore, the vaccine impacted
clinical parameters post-challenge with a homologous
BVDV strain and reduced the degree of leukopenia post-
challenge when compared to the control. The current
study does not address if the heterologous neutralization
titers indicate efficacy against heterologous challenge,
however, this will be addressed in future experiments. We
believe that BVDV E2 RP represent an attractive alterna-
tive to MLV or inactivated vaccine approaches because of
the efficacy demonstrated here, the safety profile of the
vector, and because E2 RP may allow differentiation of
infected and vaccinated animals capable of supporting
BVDV eradication programs.
The use of biohazardous materials and the calf
experimental protocol were reviewed and approved by
the ISU Institutional Biosafety Committee (IBC) and
the Institutional Animal Care and Use Committee
(9-11-7225-B).
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